Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: An improved PCR-RFLP assay for the detection of rs7662029 polymorphism
 
Yazarlar (6)
Prof. Dr. Dilek Akyüzlü Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Kırşehir Ahi Evran Üniversitesi, Türkiye
Prof. Dr. Ceylan Bal Ankara Yıldırım Beyazıt Üniversitesi, Türkiye
Dr. Öğr. Üyesi Şafak Yalçın Şahiner Kütahya Sağlık Bilimleri Üniversitesi, Türkiye
Gamze Avcıoğlu
Ankara Yildirim Beyazit University, Türkiye
Mustafa Danışman Ankara Training & Res Hosp AMATEM Clin
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (Q1)
Dergi ISSN 1382-6689 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 08-2022
Cilt / Sayı / Sayfa 94 / 6 / 103902–0 DOI 10.1016/j.etap.2022.103902
Makale Linki http://dx.doi.org/10.1016/j.etap.2022.103902
Özet
This study aimed to determine the effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on plasma buprenorphine (BUP) concentration and different treatment responses in a sample of 109 patients with opioid use disorder (OUD) treated with sublingual BUP/naloxone. Polymorphisms were analysed by PCR-RFLP. Plasma concentrations of BUP and its metabolite norbuprenorphine were detected by LC–MS/MS. Craving, withdrawal, depression and anxiety were measured by appropriate scales. OUD patients with rs7439366 CC or rs7662029 GG genotypes had significantly lower dose-normalized (BUP/D) and dose/kg-normalized BUP (BUP/D.kg-1) levels than those who were CT or AA carriers. Significant associations between UGT2B7 rs7662029 and increased craving (p = 0.037) and withdrawal symptoms (p = 0.029) were detected. Our findings were pointing to an important role of UGT2B7 in the …
Anahtar Kelimeler
UGT2B7 variation | Heroin addiction | Buprenorphine | PCR-RFLP